Back to Search
Start Over
Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin
- Source :
- Japanese journal of clinical oncology. 40(4)
- Publication Year :
- 2010
-
Abstract
- Objective We studied tau and excision repair cross-complementing 1 expression to evaluate their predictive values in advanced breast carcinoma patients. Methods Patients treated with paclitaxel and cisplatin as the first-line chemotherapy for locally advanced or metastatic breast cancer were enrolled. The expression levels of tau and excision repair cross-complementing 1 were assessed by immunohistochemistry and examined for their associations with treatment response and survival. Results Fifty-four patients were included in this study. Despite the strong association between tau expression and lower histological grade and estrogen receptor expression, tau expression remained an independent predictor for a lower response rate in multivariate analysis (odd ratio = 0.24, P = 0.02). However, tau expression was a predictor for longer overall survival in both univariate analysis (median, 57.5 vs. 30.4 months, P = 0.02) and multivariate analysis (hazard ratio = 0.36, P = 0.008). Excision repair cross-complementing 1 was not associated with treatment response or overall survival. Conclusions Tau expression but not excision repair cross-complementing 1 in advanced breast cancer predicts poor response to combination chemotherapy of paclitaxel and cisplatin. However, tau expression is significantly associated with longer overall survival.
- Subjects :
- Oncology
Adult
Cancer Research
medicine.medical_specialty
Paclitaxel
Breast Neoplasms
tau Proteins
Kaplan-Meier Estimate
Disease-Free Survival
Breast cancer
Clinical Trials, Phase II as Topic
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
medicine
Biomarkers, Tumor
Humans
Radiology, Nuclear Medicine and imaging
Aged
Retrospective Studies
Cisplatin
business.industry
Hazard ratio
Cancer
Combination chemotherapy
General Medicine
Middle Aged
medicine.disease
Endonucleases
Prognosis
Chemotherapy regimen
Metastatic breast cancer
Immunohistochemistry
DNA-Binding Proteins
Treatment Outcome
Drug Resistance, Neoplasm
Female
ERCC1
business
medicine.drug
Subjects
Details
- ISSN :
- 14653621
- Volume :
- 40
- Issue :
- 4
- Database :
- OpenAIRE
- Journal :
- Japanese journal of clinical oncology
- Accession number :
- edsair.doi.dedup.....2514d0f74f8e21fcac9f7c5e2edec30c